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Introduction. Incidence of meningioma increases with age. Surgery has been the mainstay treatment. Elderly patients, however,
are at risk of severe morbidity. Therefore, we conducted this study to analyze long-term outcomes of linac-based fractionated
stereotactic radiotherapy (FSRT) for older adults (aged ≥65 years) with meningioma and determine prognostic factors. Materials
and Methods. Between October 1998 and March 2009, 100 patients (≥65, median age, 71 years) were treated with FSRT for
meningioma. Two patients were lost to follow-up. Eight patients each had grade I and grade II meningiomas, and five patients
had grade III meningiomas. The histology was unknown in 77 cases (grade 0). Results. The median follow-up was 37 months, and
3-year, 5-year, and 10-year progression-free survival (PFS) rates were 93.7%, 91.1%, and 82%. Patients with grade 0/I meningioma
showed 3- and 5-year PFS rates of 98.4% and 95.6%. Patients with grade II or III meningiomas showed 3-year PFS rates of 36%.
93.8% of patients showed local tumor control. Multivariate analysis did not indicate any significant prognostic factors. Conclusion.
FSRTmay play an important role as a noninvasive and safe method in the clinical management of older patients with meningioma.
1. Introduction
Meningioma is the second most common primary brain
tumor. It arises from the cap cells of the arachnoidmembrane
and occurs more frequently in women than men [1].
The incidence of meningioma increases with increas-
ing age. While the incidence rate in 45–54 year olds is
4.9/100,000, this increases to 7.9/100,000 and 12.8/100,000 in
55–64 year olds and those of ≥65 years of age, respectively
[2]. A high percentage of meningiomas diagnosed present
as small, slow growing, asymptomatic tumors without brain
edema; especially in the elderly these cases are often offered
conservative clinical observation and radiologic follow-up [3,
4]. However, once the tumors become clinically symptomatic,
treatment is needed.
Surgery has traditionally been the mainstay of treatment
of symptomatic and fast growing tumors in all age groups. It
has obvious advantages in terms of removal of an expansively
growing mass. It also allows histological diagnosis, signifi-
cantly reduces neurological symptoms, and is associated with
long-term local tumor control [5, 6].
However, elderly patients may be at risk of severe com-
plications, due to limited physiological capacities and the
presence of comorbidities. A recent meta-analysis of the
effects of surgery in the older population reported that the
overall rates of complications ranged from 2.7% to 29.8%, and
the overall incidence of complications was 20% (range, 3–
61%) [7]. These findings indicate the need for careful consid-
eration when deciding to perform surgery on older patients.
Balancing the potential risks of surgery with the benefits of
alternative noninvasive procedures, including image-guided
high precision stereotactic radiotherapy (SRT), is important
for multidisciplinary decision making with regard to the
choice of treatment modality. In addition, only few studies
have evaluated the efficacy and benefits of radiotherapy for
this patient population.
In this monocentric study, we critically analyzed the
feasibility of treatment and clinical outcomes, including
tumor control and survival, in older patients (≥65 years)
with meningioma treated with linac-based fractionated SRT
(FSRT) to evaluate the advantages and limitations of SRT for
this particular patient group.
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2. Material and Methods
2.1. Treatment Decisions, Patient Selection, and Dose Regi-
mens. Our local ethics committee approved this study. The
research complied with the Helsinki Declaration. We per-
formed a retrospective analysis of 100 elderly patients (≥65)
who underwent SRT of an intracranial meningioma between
10/1998 and 03/2009. Two patients were lost to follow-up.
Follow-up data were analyzed until March 2010.
All patients underwent computed tomography and mag-
netic resonance imaging including a diffusion-weighted
series of the head. All images were evaluated by a neuroradi-
ologist. In our institution an interdisciplinary team encom-
passing radiation oncologists, neurosurgeons, pathologists,
and radiologists makes treatment decisions. Adjuvant SRT is
offered to all resected grade II and III meningioma patients;
symptomatic grade I meningiomas are treated with adjuvant
RT only after incomplete resection or when recurrence
occurs after total resection. Clinically symptomatic and fast
growing tumors that are considered inoperable either by
the anesthesiology department due to comorbidities or by
the neurosurgery department due to difficult localization are
treated using primary FSRT. Tumors are classified according
to the Novel “CLASS” Algorithmic Scale for Patient Selection
inMeningioma Surgery: low risk,medium risk, high risk, and
optical nerve sheath (ONSM) [8]. High-risk patients usually
receive FSRT rather than surgical treatment.
1.6–2Gy were considered normofractionated (nFSRT),
2.8–5Gy were considered hypofractionated (hFSRT), and
high single doses delivered in less than 5 sessions were
considered stereotactic radiosurgery (SRS). Tumors in close
proximity to critical structures were assigned to nFSRT, while
large tumors (>2 cm) distant to critical structures underwent
hFSRT and small tumors (<2 cm) were treated by SRS.
2.2. Stratification and Variables. Patients were stratified
according to grading, localization (skull base, falx/ parasagit-
tal, and convexity), predicted perioperative risk/operability,
tumor size, and sequence of therapy. Two groups were
defined: group 1 encompasses all grade I meningiomas, as
well as all meningiomas with no histology available (grade 0).
Group 2 encompasses all grade II and III meningiomas.
The tumor location was divided into 3 groups: skull base,
falx/parasagittal, and convexity.
Follow-up examinations, includingMRI as well as clinical
and neurologic examinations, were performed at 6 weeks, 3
months, 9 months, and 15 months after treatment and then
annually.
We distinguished between primary radiation treatment
and postoperative radiotherapy. Acute toxicity in the first 90
days after FSRT was graded using a modified version of the
Common Terminology Criteria of Adverse Events (CTCAE
v4.0).
2.3. Technical Set-Up. From 1995–2003 meningioma patients
underwent “sharp” fixation using a stereotactic head ring
and an oral bite plate. A 6 MV Linac (Varian USA) with an
add-on micro-multileaf collimator (mMLC) (BrainLab Co,
Germany) was used. Coordinates for SRS were set by a laser-
based stereotactic localizer. This set-up allowed delivering
shaped beams. In 2004 we started using Novalis (BrainLab)
with beam shaping capability using build-in MLC and image
guidance. Novalis ExacTrac image-guided frameless system
enabled us to image the patient at any couch position
using a frameless positioning array. MRI/CT-fusion planning
was performed. The three-dimensional treatment planning
system Brainscan (Brain Lab AG, Germany) was used, which
was later replaced by iplanRT.Thegross tumor volume (GTV)
was defined as the area of contrast enhancement on T1-
weighted MRI images; the planning target volume (PTV)
included a 2mm isotropic safety margin. The dose was
prescribed to a reference point, which was the isocenter (or
the center of GTV), though 100% was not the maximum
dose but the dose at the aforementioned reference point.
Patients received the prescribed dose to the 95% isodose at
the tumormargin.Organs at risk (OAR), such as optic nerves,
the chiasm, lenses, and the brainstem, were delineated. Dose
constraints were according to the data published by Emami
et al. 1991 [9]. The TD 5/5 to be respected was as follows: for
optic nerves 50Gy, for chiasm 50Gy, for lenses 10Gy, and for
the brainstem 50Gy, respectively.
2.4. Statistics. All statistical analyses were performed using
IBM SPSS Statistics 19 (New York, USA).
3. Results
3.1. Patient Characteristics. An initial review of medical
records revealed 100 cases of older patients (≥65) who
received FSRT for meningioma. Two patients were lost to
follow-up in the early posttherapeutic period.The remaining
98 patients included 62 women and 36 men. Histology was
unknown for 77.6% of patients, 8.2% of patients presented
with World Health Organization (WHO) grade I lesions,
8.2%presentedwith grade II lesions, and 5.1%were diagnosed
as grade III meningioma. The majority of the lesions were
located in the skull base (79.6%), 8.2%were located in the falx
or parasagittal region, and 12.2% were meningiomas of the
convexity. The median follow-up period following treatment
was 37 months. Patient characteristics are summarized in
Table 1.
3.2. Progression-Free Survival and Univariate and Multi-
variate Analysis. The results of univariate analysis (UVA)
and multivariate analysis (MVA) of predictive factors are
shown in Table 2. In the entire cohort, 3-year, 5-year, and
10-year progression-free survival (PFS) rates were 93.7%,
91.1%, and 82%, respectively (Figure 1). Patients with grade
I meningioma or unknown histology (grade 0) had 3-year
and 5-year PFS rates of 98.4% and 95.6%, respectively, while
patients with grade II or III meningioma showed a 3-year PFS
rate of 36% (Figure 2).Thedifference in PFS rates between the
grade 0/I group and the grade II/III group was statistically
significant using the Log-Rank Test (𝑃 < 0.0001).
The 3-year and 5-year PFS rates for patients who had
not undergone prior surgery were both 97.9%.The difference
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FSRT total dose (Gy) 56.5 28.8/72
hFSRT total dose (Gy) 36.3 30/42
SRS total dose (Gy) 17.6 13.5/21.4
Follow-up time in months 37 1/132
in PFS rates between the patients who had undergone prior
surgery and the patients who had not received surgical
treatment was significant using the Log-Rank Test (𝑃 < 0.01,
Figure 3).
Patients with a target volume of <6.4 cm3 did not show
significantly improved PFS rates compared to those with
target volumes >6.4 cm3. PFS rates were independent of age
(>71 versus ≤71 years), sex (male versus female), location
of tumor, and fractionation scheme. None of the factors
analyzed showed significant predictive value on multivariate
analysis.
3.3. Radiologic Response. Radiologic response rates are
shown in Table 3. Ninety-two patients (93.8%) showed local
tumor control, 21.4% of which showed tumor regression.





















Figure 1: PFS rates of the entire cohort. PFS rates were 93.7% after





























Figure 2: PFS rates of group 1 and group 2. Patients with grade I
meningioma or unknown histology showed PFS rates of 98.4% and
95.6% at 3 and 5 years, respectively; patients with grade II or III
meningioma showed PFS rates of 36% after 3 years (𝑃 < 0.0001).
3.4. Acute Toxicity. Acute toxicity data were available for 88
patients (89.8%), and of these patients, 53 (54.1%) showed
acute toxicity.Themost common acute grade I symptoms for
the entire cohort were headache, fatigue, and local alopecia.
The most common acute grade II symptoms were vertigo,
headache, and local alopecia.
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Table 2: Univariate and multivariate analysis of PFS rates. In univariate analysis localization, prior surgery and grading showed a significant
effect on prognosis (𝑃 < 0.0001, 𝑃 < 0.01, and 𝑃 < 0.0001); however multivariate analysis could not confirm these findings.
Univariate Multivariate
𝑃 value HR 95% CI 𝑃 value
Lower Upper
Age (≤71 versus >71 years) 0.24 2.87 0.32 25.43 0.35
Sex (m versus f) 0.36 3.67 0.37 35.90 0.26
Grading (unknown histology and grade I versus grade II/III) 0.0001 9.646 0.383 242.687 0.168
Localization (skull base, falx/parasagittal, and convexity) 0.0001 1.64 0.25 10.59 0.603
Target volume (≤6.4 versus >6.4 ccm) 0.54 3.41 0.38 30.72 0.27
RT regimen (FSRT versus hSRT versus SRS) 0.32 1.40 0.30 6.56 0.67
Prior surgery 0.01 4.49 0.28 71.64 0.29
Table 3: Tumor response rates.
Frequency %
Progression 6 6.1
Stable disease 71 72.4
Regression 21 21.4
3.5. Chronic Toxicity. Late toxicity data were available for 98
patients (100%), and of these patients, 16 (16.3%) showed late
toxicity. The most common grade I symptoms were fatigue,
local alopecia, and headache. No grade II or III symptoms
were found.
4. Discussion
Increased incidence of intracranial meningioma correlates
with increasing age [2, 10–14]. It is widely accepted that a
demographic shift toward an ageing population is occurring
worldwide, and this will lead to an expected increase in
the incidence of meningioma. While some data on surgical
treatment of meningioma are available [7], only few reports
focusing on the safety and efficacy of radiotherapy in older
adults have been published. Therefore, this study aimed to
explore the potential utility of a noninvasive therapeutic
procedure, high-precision image-guided FSRT,with regard to
feasibility, safety, and clinical outcomes in older patients with
meningioma [15–18].
This study shows that FSRT is feasible on the procedural
level and is safe with regard to toxicity. Furthermore, non-
invasive FSRT was effective in terms of tumor control and
survival for this ever-expanding patient group. Our results
indicate that older patients (aged≥65)may benefit fromFSRT
for the treatment of meningiomas.
In the entire cohort, 3-year, 5-year, and 10-year
progression-free survival (PFS) rates were 93.7%, 91.1%,
and 82%, respectively. This is in accordance with a recent
study carried out by Fokas et al. of 121 cases of meningioma
with a similar follow-up time (40 months) reporting local
control rates of 98.3% at 1 and 3 years and 94.7% at 5 years
[15].
We carried out UVA to examine the prognostic relevance

























Figure 3: PFS rates for patients with primary and postoperative
FSRT. There was a significant difference in PFS rates for patients
treated with primary and adjuvant FSRT (𝑃 < 0.01 Log-Rank Test).
prior surgery, and grade had an association with prognosis
(𝑃 < 0.0001, 𝑃 < 0.01, and 𝑃 < 0.0001, resp.) in
UVA. However, in agreement with the findings of Fokas
et al., (MVA, Table 2) no significant prognostic associations
with age, sex, grade, tumor localization, target volume,
radiotherapy regimen, or prior surgery were found in MVA.
With regard to toxicity outcomes, our results indicate the
safety of this treatment modality for the older population,
who is at risk of higher treatment-related complications due
to lower performance indices and comorbidities. Reports of
several surgical series in older adults have found that the
incidence of associated morbidity ranges from 9% to 54%
in this population [19–22]. The largest surgical series that
examined outcome in 258 older patients with meningioma
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indicatedmorbidity rates of 29.8% [20]. Schul et al. published
outcome data for surgically treated patients and reported a
21% rate of surgery-related morbidity [21]. Similar numbers
(17.8%) were reported by Boviatsis et al. [23]. This study, in
agreement with other studies of older patients, found that
FSRT, in contrast to surgical treatment, is a safe and effective
treatment modality for meningioma in the older population.
Our study had some limitations. Firstly the retrospective
nature of the analysis is prone to bias. Secondly, the median
follow-up was only 37 months and it is known that late
recurrences do occur in meningioma patients even after 5
years. The number of patients with more than five years of
follow-up was 𝑛 = 13. Thirdly the treatment heterogeneity
must be mentioned here, as different fractionation regimens
were used.
In conclusion, this is one of the first large studies to evalu-
ate feasibility, safety, and the efficacy of FSRT in older patients
withmeningioma.We demonstrated the safety and efficacy of
SRT in this particular patient group. The demographic shift
towards and ageing population requires innovative disease
management. Radiotherapy may play an important role as a
noninvasive, safe, and relatively cost-effective method in the
clinical management of older patients with meningioma.
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